申请人:Zeneca Limited
公开号:US06034057A1
公开(公告)日:2000-03-07
Cyclic dimeric peptides of formula (I) ##STR1## wherein: peptide 1 and peptide 2 independently represent a tetrapeptide of formula -AA1-AA2-AA3-AA4- juxtaposed in parallel or antiparallel orientation; AA1 is an L or D amino acid selected from Ile, Leu and amino analogues thereof selected from Pro, Gly, Tic and Phe; AA2 is an L amino acid selected from Leu and amino acid analogues thereof selected from Ile, Phe and Val; AA3 is an L amino acid selected from Asp, Glu and amino acid analogues thereof; AA4 is an L amino acid selected from Val and amino acid analogues thereof selected from Leu, Ile, Phe and Cha (cyclohexylalanine); L1 and L2 independently represent linking moieties for linking peptides 1 and 2 to form a cyclic dipeptide; or salts thereof. The cyclic dipeptides inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen 4 and have therapeutic applications such as in rheumatoid arthritis, asthma or multiple sclerosis.
公式(I)的环二聚肽
其中:
肽1和肽2独立地表示公式为-AA1-AA2-AA3-AA4-的四肽,其并列或反向排列;
AA1是从Ile,Leu和氨基酸类似物Pro,Gly,Tic和Phe中选择的L或D氨基酸;
AA2是从Leu和氨基酸类似物Ile,Phe和Val中选择的L氨基酸;
AA3是从Asp,Glu和氨基酸类似物中选择的L氨基酸;
AA4是从Val和氨基酸类似物Leu,Ile,Phe和Cha(环己基丙氨酸)中选择的L氨基酸;
L1和L2分别表示用于连接肽1和肽2以形成环二肽的连接基;或其盐。该环二肽抑制血管细胞粘附分子-1和纤维连接蛋白与整合素非常晚期抗原4的相互作用,并具有治疗类风湿性关节炎、哮喘或多发性硬化等应用。